/

IGC

IGC Pharma, Inc.Closed

0.2650−0.01 −3.99%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 0.2646 −0.15%

Open

0.2696

Prev close

0.2760

Day range

0.26000.2699

52-week range

0.24000.4500

Volume

422.15K0.60×

Mkt cap

27.40M

P/E ttm

—

Fwd P/E

-3.31

EPS ttm

-0.0700

Div yield

0.00%

Earnings

—

From 52w high

−41.11%

Price Chart

Yahoo Finance · delayed

IGCOct 13, 2026O 0.2700H 0.2700L 0.2600C 0.2700−0.0100 (−3.57%)Vol 422.10K

SMA 500.2828
SMA 2000.2837

1Y change −30.77% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IGC IGC Pharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.57%
1 month: −3.57%
3 months: 0.00%
6 months: −12.90%
Year to date: −3.57%
1 year: −30.77%

Valuation & ownership

Market cap: 27.40M
Enterprise value: 28.12M
P/E (ttm): —
Forward P/E: -3.31
PEG ratio: —
Price / book: 4.42
Price / sales (ttm): 24.77
EV / EBITDA: -3.74
EPS (ttm): -0.0700
EPS (forward): -0.0800
Beta (5y monthly): 0.48
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 103.38M
Float: 89.72M
Short % of float: 1.54%
Short ratio (days): 1.58
Held by insiders: 13.17%
Held by institutions: 22.09%
Avg volume (3m): 707.07K
50-day average: 0.2824
200-day average: 0.2839
52-week change: −30.77%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 42.5
vs 50-day SMA: −4.53%
vs 200-day SMA: −4.83%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.84%
Realised vol (20d, ann.): 48.8%
From 52-week high: −40.00%
From 52-week low: +12.50%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

6.00

+2,164.15% implied

Low 6.00Median 6.00High 6.00

Recommendation trend

Now1 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

DES

About IGC Pharma, Inc.

Yahoo Finance profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Sector: Healthcare
Industry: Biotechnology
Employees: 70
Headquarters: Potomac, MD, United States
Website: igcpharma.com
Officers: Mr. Ram Mukunda Founder, President, CEO & Director
Ms. Claudia Grimaldi VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
Benysh Qureshi Esq., M.B.A. Director of Operations
Mr. Rohit Goel CPA, M.B.A. Director of Accounting & Senior Director

SEAS

Seasonality · IGC

2007–2026 · monthly returns

Strongest month Feb +30.83%Weakest month Jul −6.18%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.6	3.7	-7.1	23.1	-9.4	-6.9	-7.4	20.0	-10.0	-1.9			−5.4%
2025	-5.9	-9.4	-3.4	7.1	3.3	0.0	16.1	19.4	-2.3	-4.8	-20.0	-12.5	−17.6%
2024	3.6	17.2	17.6	35.0	-9.3	-12.2	7.0	-21.7	19.4	-9.3	-5.1	-8.1	+21.4%
2023	25.0	-5.0	-10.5	2.9	-17.1	6.9	6.5	6.1	2.9	-16.7	6.7	-12.5	−12.5%
2022	-2.0	10.4	-10.4	-22.1	-41.9	23.3	0.0	5.7	-23.2	2.3	-15.9	-13.5	−67.3%
2021	1.9	10.7	1.7	-10.6	-11.3	15.5	7.9	-7.9	-9.2	-5.4	-6.4	-25.2	−37.2%
2020	0.0	-30.2	11.4	10.2	7.4	3.4	1.7	96.7	-13.3	5.8	108.2	-31.9	+147.6%
2019	32.1	562.2	-15.1	-30.3	-29.7	60.8	-26.8	-14.2	-5.8	-5.2	-16.3	-18.2	+125.0%
2018	-8.0	-25.0	-18.8	3.6	0.0	-15.5	-12.2	283.7	290.9	-78.9	-44.9	-62.7	−72.0%
2017	-3.6	18.5	46.9	-2.1	-6.5	-4.7	2.4	-26.2	16.1	19.4	34.9	72.4	+257.1%
2016	-20.8	52.6	79.3	-36.5	45.5	8.3	-7.7	-10.4	7.0	-8.7	-52.4	40.0	+16.7%
2015	-16.4	-10.7	-12.0	9.1	-14.6	-2.4	-30.0	-25.0	-9.5	-10.5	41.2	0.0	−64.2%
2014	-15.4	-9.1	-2.5	-16.7	123.1	-2.1	-28.9	-5.0	-27.1	7.1	-4.0	-6.9	−35.6%
2013	7.1	33.3	40.0	-27.9	6.4	-25.6	-20.6	-18.1	1.0	-8.6	-15.6	28.4	−25.7%
2012	-20.7	52.2	40.0	-32.7	-33.3	4.5	-13.0	0.0	-15.0	-5.9	0.0	-12.5	−51.7%
2011	39.7	-17.3	-19.4	11.1	-33.3	-5.0	-15.8	-37.5	-10.0	100.0	-8.3	-12.1	−50.0%
2010	4.3	-10.4	-9.3	42.7	-27.5	-24.0	-2.2	-27.8	81.5	-33.9	-12.8	-14.7	−58.0%
2009	2.1	-50.5	6.1	-1.9	162.7	-14.2	6.1	0.8	45.5	-10.6	-15.6	2.2	+42.3%
2008	-0.7	-1.9	-21.9	10.0	4.3	-2.9	-7.8	0.7	4.3	-34.9	-71.4	7.8	−83.6%
2007	-0.9	-1.9	2.8	-1.9	-0.2	0.3	0.0	-0.9	2.8	-1.7	0.9	1.7	+1.0%

INSD

Insider Activity · IGC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 24, 2026	Mukunda RamChief Executive Officer	Stock Gift at price 0.00 per share.	200K	—
Sep 24, 2026	Grimaldi ClaudiaChief Financial Officer	Stock Gift at price 0.00 per share.	150K	—
Jun 29, 2026	Mukunda RamChief Executive Officer	Stock Award(Grant) at price 0.27 per share.	2.23M	$601.15K
Jun 29, 2026	Grimaldi ClaudiaOfficer and Director	Stock Award(Grant) at price 0.27 per share.	2.05M	$553.06K
Mar 31, 2026	Mukunda RamChief Executive Officer	Conversion of Exercise of derivative security at price 0.26 per share.	706.4K	$84.00K
Mar 31, 2026	Prins Richard KDirector	—	170K	—
Mar 31, 2026	Grimaldi ClaudiaOfficer and Director	Conversion of Exercise of derivative security at price 0.26 per share.	238.5K	$36.00K
Mar 31, 2026	Moran James PDirector	—	130K	—
Feb 2, 2026	Mukunda RamChief Executive Officer	—	50K	—
Jan 15, 2026	Prins Richard KDirector	—	100K	—
Oct 16, 2025	Mukunda RamChief Executive Officer	Stock Gift at price 0.00 per share.	100K	—
Oct 16, 2025	Grimaldi ClaudiaOfficer and Director	Stock Gift at price 0.00 per share.	50K	—
Mar 30, 2025	Mukunda RamChief Executive Officer	—	566.7K	—
Mar 30, 2025	Prins Richard KDirector	—	228.3K	—
Mar 30, 2025	Grimaldi ClaudiaDirector	—	158.3K	—
Mar 30, 2025	Moran James PDirector	—	163.3K	—

13F

Investors Holding IGC

latest 13F filings of 29 followed managers

Investors holding IGC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$78.0K	0.00%	286.61K	−41%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IGC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IGC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IGC Pharma, Inc.

Seasonality · IGC

Insider Activity · IGC

Congress Trades · IGC

Investors Holding IGC

Investors Holding IGC

Congress Trades · IGC

Seasonality · IGC

Insider Activity · IGC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IGC Pharma, Inc.

Financial Snapshot

Earnings & Dividends

News